QuidelOrtho Fell 53% While Sales Rose

If you had backed the bullish expansion story and bought QuidelOrtho for its global footprint and decentralized testing push, the outcome has been painful. Holding QuidelOrtho from the start of the year would have meant a 53.4% loss, including dividends. If that decision felt grounded in steady 2.5% to 2.6% revenue growth, profit margin recovery to low or mid teens, and lofty P/E assumptions, what did that original case miss about debt, product mix, or pricing power?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

QuidelOrtho has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.

The Two Rival Stories Around QuidelOrtho

The shares cost US$28.56 at the start of the period, and QuidelOrtho sat between two sharply different but credible stories about its future.

The bullish case saw a Fair Value of US$40.33, built on 2.6% annual revenue growth assumptions and a move from a reported loss to a 0.6% profit margin, helped by expansion in regions like Latin America, Asia Pacific, and China.

The bearish narrative put Fair Value at US$26, with 2.5% revenue growth and a 12.5% profit margin assumption, but flagged high debt and restructuring charges as key risks that could pressure earnings quality.

What The Evidence Did To The QuidelOrtho Argument

QuidelOrtho’s plan to shrink its balance sheet moved from theory to action when it explored selling the point of care testing unit for about US$1.5b. This supported the cautious story that focused on high debt. Reported results showed revenue of US$630.9m and a loss of US$92.9m, with net margin at 14.7% below zero, so the profitability ambition in the bullish script remained unproven. Overall, the evidence cut both ways.

The key assumption was that higher sales and portfolio shifts would quickly translate into clean profits. When you assess another diagnostics stock, track whether net income and margin actually move into positive territory as management reshapes assets and discusses debt reduction.

What QuidelOrtho's Lower Price Now Asks You To Believe

QuidelOrtho trades at US$13.42 after a 53.4% loss from the start of the year, while this bullish Narrative sees Fair Value above that level.

The argument leans on cost cuts, richer recurring revenue, and new platforms. For the Narrative’s higher figure to be reached, a buyer today would need to believe those changes can lift margins materially without eroding competitive position.

"Accelerated cost-saving actions and structural expansion in recurring revenues are driving margins and earnings higher than consensus expectations. Unique market positioning and upcoming product launches could enable outsized, sustained revenue growth in underserved and rapidly expanding diagnostic segments."

The price and this Narrative do not agree. → Uncover what this Narrative says QuidelOrtho is actually worth

QuidelOrtho And A Different Route

QuidelOrtho’s story centers on diagnostics demand and how testing volumes influence earnings power.

If that theme interests you, it can help to look sideways at another healthcare group.

This larger company leans heavily on diagnostics and medical devices across several clinical areas.

Its offerings span continuous glucose monitoring, cardiac rhythm tools and cancer testing platforms.

The same patients needing QuidelOrtho’s assays may encounter this firm’s sensors, catheters or lab systems, hinting at a broader mix that could reshape its risk and reward profile.

That argument has a Narrative and a number behind it. → See the company one Narrative values 21% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com